Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 22.33 Billion KRW | -8.12% |
| 2022 | 24.3 Billion KRW | -13.23% |
| 2021 | 28.01 Billion KRW | 88.1% |
| 2020 | 14.89 Billion KRW | -47.38% |
| 2019 | 28.3 Billion KRW | 8.16% |
| 2018 | 26.16 Billion KRW | 7.67% |
| 2017 | 24.3 Billion KRW | 39.43% |
| 2016 | 17.43 Billion KRW | 254.91% |
| 2015 | 4.91 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 6.07 Billion KRW | 10.75% |
| 2024 Q2 | 5.03 Billion KRW | -17.18% |
| 2023 Q3 | 3.82 Billion KRW | -50.39% |
| 2023 Q4 | 5.48 Billion KRW | 43.4% |
| 2023 Q1 | 5.31 Billion KRW | -22.79% |
| 2023 Q2 | 7.71 Billion KRW | 45.19% |
| 2023 FY | 22.33 Billion KRW | -8.12% |
| 2022 FY | 24.3 Billion KRW | -13.23% |
| 2022 Q4 | 6.87 Billion KRW | 25.8% |
| 2022 Q3 | 5.46 Billion KRW | -6.75% |
| 2022 Q2 | 5.86 Billion KRW | -3.82% |
| 2022 Q1 | 6.09 Billion KRW | -14.1% |
| 2021 FY | 28.01 Billion KRW | 88.1% |
| 2021 Q2 | 8.71 Billion KRW | 95.3% |
| 2021 Q1 | 4.46 Billion KRW | 206.73% |
| 2021 Q4 | 7.09 Billion KRW | -8.36% |
| 2021 Q3 | 7.74 Billion KRW | -11.1% |
| 2020 Q3 | 8.31 Billion KRW | 59.92% |
| 2020 Q2 | 5.19 Billion KRW | -6.56% |
| 2020 FY | 14.89 Billion KRW | -47.38% |
| 2020 Q1 | 5.56 Billion KRW | -19.11% |
| 2020 Q4 | -4.17 Billion KRW | -150.28% |
| 2019 Q1 | 6.74 Billion KRW | -14.84% |
| 2019 FY | 28.3 Billion KRW | 8.16% |
| 2019 Q4 | 6.87 Billion KRW | -9.28% |
| 2019 Q3 | 7.58 Billion KRW | 6.72% |
| 2019 Q2 | 7.1 Billion KRW | 5.33% |
| 2018 Q3 | 6.8 Billion KRW | 15.66% |
| 2018 Q1 | 5.55 Billion KRW | 0.0% |
| 2018 FY | 26.16 Billion KRW | 7.67% |
| 2018 Q4 | 7.91 Billion KRW | 16.29% |
| 2018 Q2 | 5.88 Billion KRW | 6.04% |
| 2017 FY | 24.3 Billion KRW | 39.43% |
| 2017 Q3 | 7.28 Billion KRW | 0.0% |
| 2016 FY | 17.43 Billion KRW | 254.91% |
| 2015 FY | 4.91 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 411.002% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 61.488% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 137.479% |
| HANDOK Inc. | -28.79 Billion KRW | 177.551% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 365.386% |
| Yuhan Corporation | 93.5 Billion KRW | 76.117% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -100.79% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 190.008% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 84.728% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -536.514% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 991.025% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1176.844% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 593.56% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 411.002% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 206.647% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -523.233% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 118.883% |
| JW Holdings Corporation | 19.02 Billion KRW | -17.379% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 128.295% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 89.492% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 39.651% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 138.958% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -264.81% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -1242.485% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -346.232% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 411.002% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 39.585% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 79.971% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 39.651% |
| Yuhan Corporation | 93.5 Billion KRW | 76.117% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 237.435% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 676.249% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -264.961% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 39.651% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -18.127% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 53.726% |
| CKD Bio Corp. | -24.19 Billion KRW | 192.313% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 6.624% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 18.607% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 24.993% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 138.958% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 52.491% |
| Boryung Corporation | 40.2 Billion KRW | 44.45% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 171.283% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 991.025% |
| JW Lifescience Corporation | 28.14 Billion KRW | 20.648% |